Art. -Nr.: HY-18937

WEHI-345

3 Cited Publications

Kundenbewertung

Based on 3 publication(s) in Google Scholar

WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC₅₀ of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.29%
CAS. Nr.: 1354825-58-3
Formel: C₂₂H₂₃N₇O
Molecular Weight:401.46

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

WEHI-345 Chemical Structure

CAS. Nr.: 1354825-58-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

RIPK2

Alle RIP kinase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BMDM	IC₅₀	57.7 nM Compound: WEHI-345	Inhibition of LPS/MDP-stimulated TNFalpha production in C57BL/6J mouse BMDM cells by ELISA relative to control Inhibition of LPS/MDP-stimulated TNFalpha production in C57BL/6J mouse BMDM cells by ELISA relative to control	[PMID: 35709396]
H9c2	IC₅₀	13.07 μM Compound: WEHI-345	Toxicity in rat H9c2 cells assessed as inhibitory rate Toxicity in rat H9c2 cells assessed as inhibitory rate	[PMID: 35709396]

In Vitro

WEHI-345 (500 nM; Raw 267.4 cells) is able to inhibit MDP-induced autophosphorylation activity of RIPK2 in cells^[1].
WEHI-345 (500 nM; 0 hour, 2 hours, 4 hours, 8 hours; BMDMs or THP-1 cells) potently blocks MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in bone marrow-derived macrophages (BMDMs). In THP-1 cells, WEHI-345 reduces mRNA levels of NF-kB targets such as TNF, IL-8, IL-1b and A20^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

Raw 267.4 cells
Concentration:

500 nM
Incubation Time:
Result:

Inhibited MDP-induced autophosphorylation activity of RIPK2 in cells.

RT-PCR^[1]

Cell Line:

BMDMs or THP-1 cells
Concentration:

500 nM
Incubation Time:

0 hour, 2 hours, 4 hours, 8 hours
Result:

Blocked MDP-induced transcription of the inflammatory mediators TNF and interleukin-6 (IL-6) in BMDMs. And reduced mRNA levels of NF-kB targets in THP-1 cells.

In Vivo

WEHI-345 (20 mg/kg; intraperitoneal injection; twice daily; for 6 days; C57BL/6 male mice) treatment reduces disease score, inflammatory infiltrate, histological score and recruitment of dendritic cells to the site of inflammation. And improves body weight and reduces cytokine and chemokine levels, indicating an overall improvement of the condition in experimental autoimmune encephalomyelitis (EAE)-induced wild-type C57Bl/6 mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 male mice (8-week-old)^[1]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection; twice daily; for 6 days
Result:

Reduced disease score, inflammatory infiltrate, histological score and recruitment of dendritic cells to the site of inflammation. And improved body weight and reduced cytokine and chemokine levels.

Chemical Information

CAS. Nr. 1354825-58-3
Appearance Solid
Molecular Weight 401.46
Formel C₂₂H₂₃N₇O
Color White to off-white
SMILES

O=C(C1=CC=NC=C1)NCC(C)(N2N=C(C3=CC=C(C)C=C3)C4=C(N)N=CN=C42)C
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (3)

All WBIF

Sort by:

Journal Impact Factor

Mol Cell

Disruption of XIAP-RIP2 Association Blocks NOD2-Mediated Inflammatory Signaling. [Abstract]

2018 Feb 15;69(4):551-565.e7. PMID: 29452636

WEHI-345 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2018 Feb 15;69(4):551-565.e7. [Abstract]

THP1 cells are treated with muramyl dipeptide (MDP) for 30 min in the presence or absence of indicated kinase inhibitors (1 mM; added 1 hr prior) followed by lysis in 6 M urea buffer. Lysates are immunoprecipitated with K63 and linear ubiquitin chain antibodies, and precipitates and lysates are examined by western blotting using indicated antibodies.
EMBO J

The global phosphorylation landscape of mouse oocytes during meiotic maturation. [Abstract]

2024 Oct;43(20):4752-4785. PMID: 39256562
J Immunol

Rip2 Is Required for Nod2-Mediated Lysozyme Sorting in Paneth Cells. [Abstract]

2017 May 1;198(9):3729-3736. PMID: 28330897

WEHI-345 purchased from MedChemExpress. Usage Cited in: J Immunol. 2017 May 1;198(9):3729-3736. [Abstract]

Confocal images of lysozyme and procryptdin in cultured WT crypt organoids treated with GSK583 (5 μM) or mock-treated (A), or WEHI-345 (2.5 μM) or mock-treated (B) for 16 hours.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 25 mg/mL (62.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4909 mL

12.4545 mL

24.9091 mL

5 mM

0.4982 mL

2.4909 mL

4.9818 mL

10 mM

0.2491 mL

1.2455 mL

2.4909 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nachbur U, et al. A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nat Commun. 2015 Mar 17;6:6442. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4909 mL	12.4545 mL	24.9091 mL	62.2727 mL
	5 mM	0.4982 mL	2.4909 mL	4.9818 mL	12.4545 mL
	10 mM	0.2491 mL	1.2455 mL	2.4909 mL	6.2273 mL
	15 mM	0.1661 mL	0.8303 mL	1.6606 mL	4.1515 mL
	20 mM	0.1245 mL	0.6227 mL	1.2455 mL	3.1136 mL
	25 mM	0.0996 mL	0.4982 mL	0.9964 mL	2.4909 mL
	30 mM	0.0830 mL	0.4152 mL	0.8303 mL	2.0758 mL
	40 mM	0.0623 mL	0.3114 mL	0.6227 mL	1.5568 mL
	50 mM	0.0498 mL	0.2491 mL	0.4982 mL	1.2455 mL
	60 mM	0.0415 mL	0.2076 mL	0.4152 mL	1.0379 mL

Keywords

WEHI-345

3 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

WEHI-345

Apoptosis Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) WEHI-345

Alle RIP kinase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

WEHI-345

Apoptosis Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

Anti-Cancer Compound Library

Targeted Diversity Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) WEHI-345

Alle RIP kinase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (3)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

WEHI-345 Related Classifications

HY-18937 Related Classifications